Results 81 to 90 of about 10,024 (235)

Fullerene Derivatives for Drug Delivery against COVID-19: A Molecular Dynamics Investigation of Dendro[60]fullerene as Nanocarrier of Molnupiravir

Nanomaterials, 2022
In this paper, a theoretical investigation is made regarding the possibility of using a water-soluble derivative of C60 as a drug delivery agent for treating Coronavirus disease 2019 (COVID-19).
Georgios I. Giannopoulos
doaj   +1 more source

Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model. [PDF]

, 2022
The recent emergence of the SARS-CoV-2 Omicron variant of concern (VOC) containing a heavily mutated spike protein capable of escaping preexisting immunity identifies a continued need for interventional measures.
Bohler, WF, Feldmann, F, Feldmann, H, Griffin, AJ, Jarvis, MA, Lewis, MC, Meade-White, K, Okumura, A, Rosenke, K, Rosenke, R, Shaia, C   +10 more
core   +2 more sources

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study

Clinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression. Molnupiravir is rapidly absorbed and hydrolyzed to deliver NHC into systemic circulation.
Jixiang Zhu, Danning Zhang, Zhiping Liu, Bei Yan, Yanqiao Zang, Weiwei Zhao, Fang Sun, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch, Haiyan Li   +10 more
wiley   +1 more source

Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19

Биопрепараты: Профилактика, диагностика, лечение, 2022
Finding effective and safe medicines to fight SARS-CoV-2 infection is an urgent task. RPH-137 is an original trap fusion protein against SARS-CoV-2 virus.
E. V. Shipaeva, O. V. Filon, A. V. Zintchenko, G. A. Shipunov, A. A. Dmitrieva, M. S. Lemak, S. A. Grishin, E. I. Trofimets, K. L. Kryshen, L. I. Kozlovskaya, A. S. Lunin, V. D. Apolokhov, S. F. Barbashov, Ya. V. Lavrovsky, M. Yu. Samsonov   +14 more
doaj   +1 more source

Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong [PDF]

, 2023
Importance: Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a common comorbidity in patients with acute COVID-19 and is proven to be a key determinant of COVID-19 prognosis.
Au, Ivan CH, Chung, Matthew SH, Cowling, Benjamin J, Lau, Eric HY, Lau, Kristy TK, Lee, Chi Ho, Lui, David TW, Wong, Carlos KH, Woo, Yu Cho   +8 more
core   +1 more source

Concise two-step chemical synthesis of molnupiravir

RSC Advances, 2022
Fast, effective and chromatography column-free chemical synthesis of molnupiravir.
Vinícius R. D. Pereira, Marco A. M. Bezerra, Mauro R. B. P. Gomez, Guilherme M. Martins, Adilson D. da Silva, Kleber T. de Oliveira, Rodrigo O. M. A. de Souza, Giovanni W. Amarante   +7 more
openaire   +2 more sources

Frequency and Duration of the Clinical Symptoms of Patients With Mild COVID‐19: A Comparison With Influenza in the 2023–2024 Japanese Influenza Season, an Observational Study

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims This study aimed to compare the clinical symptoms of mild COVID‐19 and influenza during a period when both diseases circulated in the 2023–2024 influenza season in Japan. Methods Outpatients diagnosed with COVID‐19, influenza A, or influenza B by antigen test kits at 10 medical facilities in Japan were enrolled.
Takuma Bando, Hideyuki Ikematsu, Naoki Kawai, Tetsunari Maeda, Woon Joo Lee, Shinro Matsuura, Osame Tanaka, Takashi Kawashima, Hareaki Yamamoto, Ietaka Sato, Ken‐ichi Doniwa   +10 more
wiley   +1 more source

The Fitness of Molnupiravir-Signed SARS-CoV-2 Variants: Imputation Analysis Based on Prescription Counts and Global Initiative on Sharing All Influenza Data Analyses by Country

Intervirology
Introduction: Molnupiravir is one of the oral direct-acting antivirals against SARS-CoV-2, largely deployed during the COVID-19 pandemic since the 2022 Omicron wave. While efficacy has been questioned in post-marketing clinical trials (leading
Daniele Focosi, Dave McNally, Fabrizio Maggi   +2 more
doaj   +1 more source

Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience [PDF]

, 2022
Since the start of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, several treatments have been proposed to cure coronavirus disease 2019 (COVID-19) and prevent it.
Babudieri, Sergio, Bacciu, Sara, Bitti, Alessandra, Colpani, Agnese, De Vito, Andrea, Denti, Lucia, Fois, Marco, Madeddu, Giordano, Maida, Ivana, Marcia, Claudia, Meloni, Maria Chiara, Zauli, Beatrice   +11 more
core   +1 more source

Are Tetrapleura tetraptera Phytochemicals Druggable Against SARS‐CoV‐2 Papain‐Like Protein? A Computational Approach

New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.
SARS‐CoV2 Omicron and its substrains are still a critical global health issue and extremely contagious, even with widespread vaccination efforts. Hospitalizations and mortality rates linked to these variants are still prevalent. Current therapeutic options face challenges, including low effectiveness, suboptimal pharmacokinetics, and drug resistance ...
Frank Eric Tatsing Foka, Hazel Tumelo Mufhandu   +1 more
wiley   +1 more source